TY  - JOUR
AU  - Choi, Bryan D.
AU  - Curry, William T.
PY  - 2017
TI  - IDH mutational status and the immune system in gliomas: a tale of two tumors?
JF  - Translational Cancer Research; Vol 6, Supplement 7 (October 24, 2017): Translational Cancer Research
Y2  - 2017
KW  - 
N2  - Gliomas are the most common type of primary brain tumor and include glioblastoma (GBM), which is the most lethal form of the disease, and remains a significant, unmet clinical need (1). Contrary to conventional notions of central nervous system immune-privilege, there is indeed extensive cross-talk between the immune system and tumors in the brain. Several successful immune therapies are either in development or have received recent approval from the Food and Drug Administration across a broad array of cancers (Table 1). However, the results for immune therapy against solid tumors in the brain have been less dramatic to date.
UR  - https://tcr.amegroups.org/article/view/16582